Watch hVIVO’s July 2024 Capital Markets Day here
We are a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials, providing end-to-end early clinical development services to our broad and longstanding client base of biopharma companies.
Yamin 'Mo' Khan
CEO at hVIVO
“After an exceptionally strong first half with record revenues and margins, hVIVO enters the remainder of the year with FY24 revenue guidance fully contracted and good visibility into 2025. We continue to expand our pipeline, not only in human challenge trials but also in our new revenue streams including clinical site studies, standalone laboratory services, and participant / patient recruitment. Operational efficiencies are set to continue to improve with the expansion of our services, improved automation, and the move to our new facility in Canary Wharf.
“We are pleased to reaffirm our full-year revenue guidance of £62 million and expect EBITDA margins to be at the upper end of market expectations*. We are targeting Group revenue of £100 million by 2028 – this growth will be underpinned by the increased capacity of our facilities, our strong cash position, and our long-term sustainable growth model.”
H124 Revenue
H124 EBITDA Margin
Cash 30 June 2024
2024 Revenue Guidance
Strong market dynamics
Scalable infrastructure
Trusted partner
Orderbook growth
Our values
We are a diverse group of individuals working for one team to achieve common goals. Each one of us plays a crucial role in the team's success. We are committed to each other and the team. We learn from our failures together and celebrate our successes together. Diversity and inclusion are at the core of our organisation, and we consider our clients’ success as our own.
We are dedicated to the growth of our colleagues, customers and shareholders. We are committed to our personal growth and the development of our colleagues. We aim to grow our client base and the value of their products. We will repay the trust of our shareholders in achieving greater returns on their investment. We will achieve this by creating a culture of intellectual freedom across the organisation.
We take personal ownership of our actions and always act in ways that builds trust and respect with all our stakeholders. We pride ourselves in maintaining the welfare and the rights of all individuals and ensuring the best outcomes for our participants and patients. We are honest, have strong moral and ethical principles and are reliable and consistent in our delivery.
We are pioneering in our approach, always curious. We use our unique scientific expertise to guide our client’s towards successful outcomes. We embrace new opportunities and rise to new challenges. Our agility allows us to redefine our markets and be highly responsive to our clients’ requirements.
